{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:54:27Z","timestamp":1773701667634,"version":"3.50.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Neuronal glycogen synthase kinase-3s (GSK-3\u03b1 and the more abundant GSK-3\u03b2) are serine\/threonine kinases that have been postulated to play roles in neuronal adaptations, including those that come from exposures to substances of abuse; however, there is only modest information about ways in which GSK-3 alters the effects of the widely abused psychostimulant, methamphetamine (METH). To evaluate the effects of GSK-3 inhibition on METH-induced symptoms, mice were treated with LY2090314, a potent and selective GSK-3 inhibitor, followed by METH. Horizontal locomotion, vertical rearing, and stereotyped behaviors were measured. Pretreatment with LY2090314 (2.5, 10, and 25\u2005mg\/kg) significantly inhibited stereotypic behavior induced by METH (10\u2005mg\/kg) in a dose-dependent fashion. Stereotyped biting was most robustly reduced by LY2090314. By contrast, LY2090314 had no significant effect on METH (3\u2005mg\/kg)-induced hyperlocomotion. GSK-3 signaling pathways appear to be differentially involved in acute METH effects on locomotion. GSK-3 appears essential for the expression of METH-induced stereotypy but not hyperlocomotion.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000853","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T10:00:19Z","timestamp":1759140019000},"page":"579-587","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pretreatment with LY2090314, a potent glycogen synthase kinase-3 inhibitor, suppresses methamphetamine-induced stereotyped behavior but not hyperlocomotion in mice"],"prefix":"10.1097","volume":"36","author":[{"given":"Kentaro","family":"Matsuda","sequence":"first","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobue","family":"Kitanaka","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe"},{"name":"Department of Pharmacology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank Scott","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hamana","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Nakai","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Yuze","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Applied Pharmacology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Applied Pharmacology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Applied Pharmacology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George R.","family":"Uhl","sequence":"additional","affiliation":[{"name":"Department of Neurology, VA Maryland Healthcare System"},{"name":"Departments of Neurology and Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kitanaka","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University, Kobe"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/YPG.0b013e3283539528","article-title":"Association study of the beta-arrestin 2 gene (ARRB2) with opioid and cocaine dependence in a European-American population.","volume":"22","author":"Ambrose-Lanci","year":"2012","journal-title":"Psychiatr Genet"},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"e0125028","DOI":"10.1371\/journal.pone.0125028","article-title":"Activating the Wnt\/\u03b2-catenin pathway for the treatment of melanoma \u2013 application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3.","volume":"10","author":"Atkinson","year":"2015","journal-title":"PLoS One"},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuron.2013.10.052","article-title":"Histidine decarboxylase deficiency causes Tourette syndrome: parallel findings in humans and mice.","volume":"81","author":"Baldan","year":"2014","journal-title":"Neuron"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"118746","DOI":"10.1016\/j.bbamcr.2020.118746","article-title":"Glycogen synthase kinase-3 signaling in cellular and behavioral responses to psychostimulant drugs.","volume":"1867","author":"Barr","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1096\/fj.07-102442","article-title":"Modulation of voluntary ethanol consumption by beta-arrestin 2.","volume":"22","author":"Bjork","year":"2008","journal-title":"FASEB J"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00213-013-3166-x","article-title":"Beta-arrestin 2 knockout mice exhibit sensitized dopamine release and increased reward in response to a low dose of alcohol.","volume":"230","author":"Bjork","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"10265","DOI":"10.1523\/JNEUROSCI.23-32-10265.2003","article-title":"Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice.","volume":"23","author":"Bohn","year":"2003","journal-title":"J Neurosci"},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0897190011426557","article-title":"Treatments for methamphetamine abuse: a literature review for the clinician.","volume":"24","author":"Brackins","year":"2011","journal-title":"J Pharm Pract"},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2014.08.003","article-title":"Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.","volume":"143","author":"Courtney","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1432-1033.1980.tb06059.x","article-title":"Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase.","volume":"107","author":"Embi","year":"1980","journal-title":"Eur J Biochem"},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bbr.2012.03.027","article-title":"Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse.","volume":"231","author":"Enman","year":"2012","journal-title":"Behav Brain Res"},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/syn.21642","article-title":"Glycogen synthase kinase-3\u03b2 (GSK3\u03b2) expression in a mouse model of Alzheimer\u2019s disease: a light and electron microscopy study.","volume":"67","author":"Gandy","year":"2013","journal-title":"Synapse"},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1017\/S1461145704004535","article-title":"AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test.","volume":"7","author":"Gould","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.109.153049","article-title":"3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis.","volume":"332","author":"Gurrieri","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.irn.2015.02.004","article-title":"Neuropsychiatric adverse effects of amphetamine and methamphetamine.","volume":"120","author":"Harro","year":"2015","journal-title":"Int Rev Neurobiol"},{"key":"R16-20251107","doi-asserted-by":"crossref","first-page":"115109","DOI":"10.1016\/j.bcp.2022.115109","article-title":"Substrate-selective positive allosteric modulation of PTPRD\u2019s phosphatase by flavonols.","volume":"202","author":"Henderson","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1601-183X.2006.00237.x","article-title":"Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia.","volume":"6","author":"Ikeda","year":"2007","journal-title":"Genes Brain Behav"},{"key":"R18-20251107","first-page":"704","article-title":"Dose-dependent response of central dopaminergic systems to buspirone in mice.","volume":"46","author":"Jadhav","year":"2008","journal-title":"Indian J Exp Biol"},{"key":"R19-20251107","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2125.2010.03639.x","article-title":"Pharmacological approaches to methamphetamine dependence: a focused review.","volume":"69","author":"Karila","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20251107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-2999(03)02015-6","article-title":"Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration.","volume":"474","author":"Kitanaka","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"R21-20251107","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.neuroscience.2007.05.006","article-title":"Blockade of brain histamine metabolism alters methamphetamine-induced expression pattern of stereotypy in mice via histamine H1 receptors.","volume":"147","author":"Kitanaka","year":"2007","journal-title":"Neuroscience"},{"key":"R22-20251107","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00213-008-1425-z","article-title":"Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice.","volume":"203","author":"Kitanaka","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"R23-20251107","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/FBP.0000000000000030","article-title":"Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice.","volume":"25","author":"Kitanaka","year":"2014","journal-title":"Behav Pharmacol"},{"key":"R24-20251107","first-page":"1","article-title":"Pretreatment or Posttreatment with aripiprazole attenuates methamphetamine-induced stereotyped behavior in mice.","volume":"9","author":"Kitanaka","year":"2015","journal-title":"J Exp Neurosci"},{"key":"R25-20251107","doi-asserted-by":"crossref","first-page":"146873","DOI":"10.1016\/j.brainres.2020.146873","article-title":"In vivo evaluation of effects of histamine H(3) receptor antagonists on methamphetamine-induced hyperlocomotion in mice.","volume":"1740","author":"Kitanaka","year":"2020","journal-title":"Brain Res"},{"key":"R27-20251107","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0891-0618(99)00012-5","article-title":"Developmental expression and localization of glycogen synthase kinase-3 beta in rat brain.","volume":"16","author":"Leroy","year":"1999","journal-title":"J Chem Neuroanat"},{"key":"R28-20251107","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1073\/pnas.1421758112","article-title":"Beta-arrestin-biased signaling mediates memory reconsolidation.","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-20251107","doi-asserted-by":"crossref","first-page":"113809","DOI":"10.1016\/j.expneurol.2021.113809","article-title":"Levo-tetrahydropalmatine: a new potential medication for methamphetamine addiction and neurotoxicity.","volume":"344","author":"Liu","year":"2021","journal-title":"Exp Neurol"},{"key":"R30-20251107","doi-asserted-by":"crossref","first-page":"jcs229948","DOI":"10.1242\/jcs.229948","article-title":"CHIR-99021 regulates mitochondrial remodelling via \u03b2-catenin signalling and miRNA expression during endodermal differentiation.","volume":"132","author":"Ma","year":"2019","journal-title":"J Cell Sci"},{"key":"R31-20251107","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.neuroscience.2012.09.020","article-title":"Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: evidence for the mechanisms of action.","volume":"226","author":"Mazzardo-Martins","year":"2012","journal-title":"Neuroscience"},{"key":"R32-20251107","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11064-008-9770-1","article-title":"GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide.","volume":"34","author":"Pandey","year":"2009","journal-title":"Neurochem Res"},{"key":"R33-20251107","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drugalcdep.2012.11.016","article-title":"Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings.","volume":"129","author":"Panenka","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R34-20251107","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00005072-199701000-00007","article-title":"Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain.","volume":"56","author":"Pei","year":"1997","journal-title":"J Neuropathol Exp Neurol"},{"key":"R35-20251107","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000360158","article-title":"Dopamine D\u2081-D\u2082 receptor heteromer regulates signaling cascades involved in addiction: potential relevance to adolescent drug susceptibility.","volume":"36","author":"Perreault","year":"2014","journal-title":"Dev Neurosci"},{"key":"R36-20251107","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1073\/pnas.1502742112","article-title":"Elucidation of G-protein and beta-arrestin functional selectivity at the dopamine D2 receptor.","volume":"112","author":"Peterson","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R37-20251107","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","article-title":"Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review.","volume":"34","author":"Siefried","year":"2020","journal-title":"CNS Drugs"},{"key":"R38-20251107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1471-4159.1994.63010245.x","article-title":"Localization and developmental changes of tau protein kinase I\/glycogen synthase kinase-3 beta in rat brain.","volume":"63","author":"Takahashi","year":"1994","journal-title":"J Neurochem"},{"key":"R39-20251107","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/neurosci2040033","article-title":"GSK3\u03b2 activity in reward circuit functioning and addiction.","volume":"2","author":"Turlik","year":"2021","journal-title":"NeuroSci"},{"key":"R40-20251107","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/nyas.14002","article-title":"PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.","volume":"1451","author":"Uhl","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"R41-20251107","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1073\/pnas.1720446115","article-title":"Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.","volume":"115","author":"Uhl","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-20251107","doi-asserted-by":"crossref","first-page":"114646","DOI":"10.1016\/j.physbeh.2024.114646","article-title":"Clavulanic acid inhibits methamphetamine locomotor sensitization in mice and normalizes methamphetamine-induced changes in glutaminase mRNA levels in the nucleus accumbens.","volume":"284","author":"Walters","year":"2024","journal-title":"Physiol Behav"},{"key":"R43-20251107","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1471-4159.2011.07281.x","article-title":"Glycogen synthase kinase 3beta in the nucleus accumbens core is critical for methamphetamine-induced behavioral sensitization.","volume":"118","author":"Xu","year":"2011","journal-title":"J Neurochem"},{"key":"R44-20251107","first-page":"178","article-title":"[beta-arrestin 2 plays a critical role in reward behaviors induced by cocaine].","volume":"65","author":"Yin","year":"2013","journal-title":"Sheng Li Xue Bao"},{"key":"R45-20251107","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1124\/dmd.112.048488","article-title":"Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.","volume":"41","author":"Zamek-Gliszczynski","year":"2013","journal-title":"Drug Metab Dispos"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:01:39Z","timestamp":1762509699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000853","relation":{},"ISSN":["0955-8810","1473-5849"],"issn-type":[{"value":"0955-8810","type":"print"},{"value":"1473-5849","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"2025-04-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}